BIOBANKING IN TIMES OF COVID19 – PRE-ANALYTICAL PROCESSES

ANDREA WUTTE
HEAD OF BBMRI-ERIC QM SERVICES
BBMRI-ERIC QUALITY MANAGEMENT SERVICES FOR BASIC AND APPLIED RESEARCH

**KNOWLEDGE HUB**

- Find everything you need to know about quality management in biobanking and biomedical research in one place.
- The BBMRI-QM Knowledge Hub is a database of experts in the field to help you with any of the following:
  - International standards relevant for biobanking and biomedical research.
  - Quality management tasks in EU projects.
  - Quality management contribution to national and international research project proposals.
  - Specific questions you may have.
  - Biobanking in times of COVID-19.

**TRAINING & SUPPORT**

- Whether you are looking for training opportunities or practical support with your quality management – quality experts can provide you with a solution tailored to your needs.
- Within the BBMRI-QM network, we offer in-house and online training, university courses, summer schools, short courses, workshops, and consulting services covering different quality management systems.
- International standards relevant for biomedical research.
- General quality management systems.
- Integrated quality management systems.

**AUDITING**

- Request an audit from BBMRI-ERIC.
- If you run a non-certified biobank and/or you want to know if the samples stored fulfill certain quality requirements, get the support from BBMRI-QM. We offer peer-review style audits on request. Take the next QM improvement step together with us!
- BBMRI-ERIC Self-Assessment Survey for biobanks.
- What is the BBMRI-ERIC Self-Assessment Survey? How does it work? More details...
- BBMRI-ERIC Audit.
BBMRI.QM WEB CONFERENCE

Web conference #2 will take place on 7 April 2020:
BIOBANKING IN TIMES OF COVID-19,
PRE-ANALYTICAL PROCEDURES

Aim
This web conference is aimed at biobanking experts and researchers. We will follow up on the open questions raised in the first web conference and, in addition, we will focus on pre-analytical procedures in the hospital and biobanking setting.

"Routine processing of COVID-19 samples from the bedside to the laboratory and to the biobank" will be addressed, and we will discuss whether researchers have any "additional requirements for the sample quality", when thinking of any scientifically driven downstream analysis.

Together with Lukasz Kozera, colleagues and partners from the biobanking community, I will address your questions and together we will try to give answers while incorporating your expertise.

The web conference will take place on 7 April 2020, 10:00-12:00 am CET.
Join us!

Web conference #1 took place on 1 April 2020:
BIOBANKING IN TIMES OF COVID-19,
RISKS AND OPPORTUNITIES FOR BIOBANKS

Aim and Agenda
Follow this link

Recording
Follow this link

Presentations
Petr Holak - BBMRI-ERIC Director and Negator for COVID
Manuel Bradley - CMO BBMRI COVID
Andrea Genna - COVID-19 Rapid Global资产 Response Genetics Initiative

AW_07 April 2020
Documents

WHO
- Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020
- Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection: interim guidance, 10 January 2020
- Guidance for laboratories shipping specimens to WHO reference laboratories that provide confirmatory testing for COVID-19 virus: interim guidance, 2 March 2020

CDC/USA
- Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
- Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)

ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE/CHINA
- Handbook of COVID-19 Prevention and Treatment

UCSF/USA
- UCSF Guidelines for Research Biospecimens during the COVID-19 Outbreak
Biobanking in Times of COVID-19,
#1 Risks and Opportunities (April 1, 2020)
#2 Pre-Analytical Processes (April 7, 2020)

Questions and Answers

Q: Can Biobanks around the world be included in the COVID BE
A: Yes, the BBMRI-ERIC offers to include biobanks in the Direc
eric.eu/menu/main/app-molgenis-app-biobank-explorer/bioba
presentation of Petr Holub on BBMRI-ERIC website

Q: A general question: I believe it would be also feasible to loo
genetic information that you have collected. Standardized met
patient stratification (after positive testing) and thereafter for t
responder). If someone is interested I shall be happy to share it
A: contact: bijon.chatterji@biocrates.com

Q: What type of samples are you collecting right now? Since w
studies will be carried out. We are not sure what type of sample
Serum?
A: See presentation of Lukasz Koza 7 April 2020 on the BBM

Q: It should be useful to know about other biological samples
A: In any case handling biological sample is recommended to b
Guide https://apps.who.int/iris/bitstream/handle/10665/3
eng.pdf?sequence=1&isAllowed=y

Q: Any partnerships with any African countries for samples/data since the prevalence of the disease there is low?
A: African biobanks can be included in the Directory see https://directory.bbmri-
eric.eu/menu/main/app-molgenis-app-biobank-explorer/biobankexplorer

Q: What should those of us who run biobanks in countries where COVID19 has not really taken hold (yet)? What should we do to prepare for as biobankers? Advice please.
A: Follow the web conference on 7 April 2020 and see the presentation of Lukasz Koza and
Helmut Haslacher on the BBMRI-ERIC website

Q: How will BBMRI work with countries, especially China, that cannot send samples outside their borders?
A: Chinese biobanks can be included in the Directory see https://directory.bbmri-
eric.eu/menu/main/app-molgenis-app-biobank-explorer/biobankexplorer

Q: Could you also please share the links where we could try to find all the documents related to the safety regulations and the quality of samples and their associated data?
A: See a list of documents https://www.bbmi-eric.eu/services/bbmriqm-covid and
https://www.bbmi-eric.eu/services/standardization/

Q: Is there support available to enable researchers and biobanks to put in the right paperwork
contracts, MTA’s etc) in place to actually get those samples sent from the biobanks to the
researchers?
A:

CLINICAL ASPECTS AND BIOBANKING

Q: What about asymptomatic patients in high risk population?
# TABLE OF CONTENT

1 Scope
2 Normative references
3 Terms and definitions
4 General requirements
5 Structural requirements
6 Resource requirements
7 Process requirements
8 Quality management system requirements
Annex A (normative) Documentation requirements
Annex B (informative) Implementation guidance for Annex A
Annex C (informative) Quality management system options
Bibliography
BBMRI.QM WEBCON SERIES

ON THE NEW BIOBANKING STANDARD
ISO 20387:2018 “BIOTECHNOLOGY – BIOBANKING –
GENERAL REQUIREMENTS FOR BIOBANKING”

From April 2019 to February 2020 the BBMRI.QM team provided our members and observers with an in-depth training on the new international standard “General Requirements for Biobanking, ISO 20387:2018”.

This BBMRI-ERIC training and education programme has been presented as an online course, split into 22 sessions in which the individual chapters of the standard were discussed. Renowned experts gave comprehensive presentations on requirements, and 225 registrants from our members attended the presentations regularly. The webinars are recorded and can be accessed at any time.

How have we been doing so far?

If you are part of the BBMRI-ERIC community and would like to have access to the recordings of our web conference series, please contact our Quality Management team:

Andrea Wutte / Quality Management andrea.wutte@bbmri-eric.eu
Daniela Krasner / Quality Management Officer daniela.krasner@bbmri-eric.eu
Nadja Palko / QM Service Officer nadja.palko@bbmri-eric.eu

BBMRI-ERIC is member state driven, serving public organisations (universities, hospitals, biobanks and their associated researchers). Within our member and observer countries we are offering free access to our services. No free access for private sector (industry, business enterprise, SMEs, etc.), access on request.
UNDERSTANDING COVID-19

A rapid, comprehensive, and relevant update on the current state of COVID-19, with attention to the epidemiology, clinical presentation, and emerging therapeutic options.

4/7/2020

When: April 7, 2020
9:00am PST/12:00pm EST

Where: United States